

				PTO/SB/055 (12-08) Approved for use through 01/31/2009. OMB 0681-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.				
				<b>Complete if Known</b>
Substitute for form 1449/PTO				
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				
Sheet	1	of	2	Attorney Docket Number
MUR-06-1101				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Bongartz, T. et al., "Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis: a Population-Based Study," <u>Arthritis &amp; Rheumatism</u> , June 1010, vol. 62, no. 6, pages 1583-1591.	
		Chaouat, A. et al., "Pulmonary Hypertension: Basic Concepts for Practical Management," <u>European Respiratory Journal</u> , 2008, vol. 32, no. 5, pages 1371-1385.	
		Crosby, L.M. et al., "Epithelial Repair Mechanisms in the Lung," <u>Am. J. Physiol. Lung Cell Mol. Physiol.</u> , June 2010, vol. 298, pages L715-L731.	
		Dumin, J.A. et al., "Pro-Collagenase-1 (Matrix Metalloproteinase-1) Binds the $\alpha_2\beta_1$ Integrin upon Release from Keratinocytes Migrating on Type I Collagen," <u>The Journal of Biological Chemistry</u> , August 3, 2001, vol. 276, no. 31, pages 29368-29374.	
		Festuccia, C. et al., "Bombesin-Dependent Pro-MMP-9 Activation in Prostatic Cancer Cells Requires $\beta 1$ Integrin Engagement," <u>Experimental Cell Research</u> , 2002, vol. 280, pages 1-11.	
		Fischer, C. et al., "Lymphocyte-Endothelial Interactions in Inflamed Synovia: Involvement of Several Adhesion Molecules and Integrin Epitopes," <u>Scand. J. Immunol.</u> , 1993, vol. 38, no. 158, pages 158 to 166.	
		Hung, W.W. et al., "Cognitive Decline among Patients with Chronic Obstructive Pulmonary Disease," <u>Am. J. Respir. Crit. Care Med.</u> , 2009, vol. 180, pages 134-137 (2009).	
		Kozora, E. et al., "Cognitive Functioning in Patients with Chronic Obstructive Pulmonary Disease and Mild Hypoxemia Compared with Patients with Mild Alzheimer Disease and Normal Controls," <u>Neuropsychiatry, Neuropsychology, and Behavioral Neurology</u> , 1999, vol. 12, no. 3, pages 178-183.	
		Levkau, B. et al., "Activation of Metalloproteinases and their Association with Integrins: an Auxiliary Apoptotic Pathway in Human Endothelial Cells," <u>Cell Death and Differentiation</u> , 2002, vol. 9, pages 1360-1367.	
		Lim, S. et al., "Balance of Matrix Metalloprotease-9 and Tissue Inhibitor of Metalloprotease-1 from Alveolar Macrophages in Cigarette Smokers: Regulation by Interleukin-10," <u>American Journal of Respiratory and Critical Care Medicine</u> , 2000, vol. 162, pages 1355-1360.	

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO.				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/576,274
Sheet	2	of	2	Filing Date	April 17, 2006
				First Named Inventor	Rehab Al-Jamal et al.
				Art Unit	1644
				Examiner Name	Maher M. Haddad
				Attorney Docket Number	MUR-06-1101

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Lo Coco D. et al., "Increased Frequency of Restless Legs Syndrome in Chronic Obstructive Pulmonary Disease Patients," <u>Sleep Medicine</u> , 2009, vol. 10, pages 572-576.	
		Luo, B.H. et al., "Allosteric $\beta_1$ Integrin Antibodies that Stabilize the Low Affinity State by Preventing the Swing-Out of the Hybrid Domain," <u>The Journal of Biological Chemistry</u> , June 25, 2004, vol. 279, no. 26, pages 27466-27471.	
		Murphy, D.B et al., "Adverse Ventilatory Strategy Causes Pulmonary-to-Systemic Translocation of Endotoxin," <u>American Journal of Respiratory and Critical Care Medicine</u> , 2000, vol. 162, pages 27-33.	
		Ortakamuk, H. et al., "Brain Perfusion Abnormalities in Chronic Obstructive Pulmonary Disease: Comparison with Cognitive Impairment," <u>Annals of Nuclear Medicine</u> , 2006, vol. 20, no. 2, pages 99-106.	
		Saito, Y. et al., "Potentiation of Cell Invasion and Matrix Metalloproteinase Production by $\alpha 3\beta 1$ Integrin-Mediated Adhesion of Gastric Carcinoma Cells to Laminin-6," <u>Clin. Exp. Metastasis</u> , 2010, vol. 27, pages 197-205.	
		Shapiro, S.D. et al., "Activation of the 92-kDa Gelatinase by Stromelysin and 4-Aminophenylmercuric Acetate," <u>The Journal of Biological Chemistry</u> , March 17, 1995, vol. 270, no. 11, pages 6351-6356.	
		Tremblay, L. et al., "Injurious Ventilatory Strategies Increase Cytokines and c-fos mRNA Expression in an Isolated Rat Lung Model," <u>J. Clin. Invest.</u> , March 1997, vol. 99, no. 5, pages 944-952.	
		Tsuji, T. et al., "Regulation of Melanoma Cell Migration and Invasion by Laminin-5 and $\alpha 3\beta 1$ Integrin (VLA-3)," <u>Clinical &amp; Experimental Metastasis</u> , 2002, vol. 19 pages 127-134.	
		Wang, J. et al., "Neuroprotection by Inhibition of Matrix Metalloproteinases in a Mouse Model of Intracerebral Haemorrhage," <u>Brain</u> , 2005, vol. 128, pages 1622-1633.	
		Zhao, B-Q. et al., "Role of Matrix Metalloproteinases in Delayed Cortical Responses after Stroke," <u>Nature Medicine</u> , April 2006, vol. 12, no. 4, pages 441-445.	

Examiner Signature	/Maher Haddad/	Date Considered	12/28/2010
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.